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Background: Laminopathies, due to mutations in LMNA, encoding A type-lamins, can lead to premature ageing
and/or lipodystrophic syndromes, showing that these diseases could have close physiopathological relationships.
We show here that lipodystrophy and extreme insulin resistance can also reveal the adult progeria Werner
syndrome linked to mutations in WRN, encoding a RecQ DNA helicase.
Methods: We analysed the clinical and biological features of two women, aged 32 and 36, referred for partial
lipodystrophic syndrome which led to the molecular diagnosis of Werner syndrome. Cultured skin fibroblasts from
one patient were studied.
Results: Two normal-weighted women presented with a partial lipodystrophic syndrome with hypertriglyceridemia
and liver steatosis. One of them had also diabetes. Both patients showed a peculiar, striking lipodystrophic
phenotype with subcutaneous lipoatrophy of the four limbs contrasting with truncal and abdominal fat
accumulation. Their oral glucose tolerance tests showed extremely high levels of insulinemia, revealing major
insulin resistance. Low serum levels of sex-hormone binding globulin and adiponectin suggested a post-receptor
insulin signalling defect. Other clinical features included bilateral cataracts, greying hair and distal skin atrophy. We
observed biallelic WRN null mutations in both women (p.Q748X homozygous, and compound heterozygous p.
Q1257X/p.M1329fs). Their fertility was decreased, with preserved menstrual cycles and normal follicle-stimulating
hormone levels ruling out premature ovarian failure. However undetectable anti-müllerian hormone and inhibin B
indicated diminished follicular ovarian reserve. Insulin-resistance linked ovarian hyperandrogenism could also
contribute to decreased fertility, and the two patients became pregnant after initiation of insulin-sensitizers
(metformin). Both pregnancies were complicated by severe cervical incompetence, leading to the preterm birth of
a healthy newborn in one case, but to a second trimester-abortion in the other. WRN-mutated fibroblasts showed
oxidative stress, increased lamin B1 expression, nuclear dysmorphies and premature senescence.
Conclusions: We show here for the first time that partial lipodystrophy with severe insulin resistance can reveal
WRN-linked premature aging syndrome. Increased expression of lamin B1 with altered lamina architecture observed
in WRN-mutated fibroblasts could contribute to premature cellular senescence. Primary alterations in DNA
replication and/or repair should be considered as possible causes of lipodystrophic syndromes.
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The studies of clinical and cellular consequences of
LMNA mutations in humans have provided several indica-
tions of a close physiopathological relationship between
premature aging and lipodystrophic syndromes. Indeed,
human naturally-occuring LMNA mutations, among other
phenotypes of laminopathies, have been shown to be re-
sponsible for premature ageing syndromes (Hutchinson-
Gilford progeria, HGPS, and mandibuloacral dysplasia,
MAD) [1-4], lipodystrophic syndromes (familial partial
lipodystrophy of the Dunnigan type, FPLD2) [5,6], and
mixed phenotypes [7-10]. At the cellular level, a highly
similar disorganization of the nuclear lamina is observed
in fibroblasts from patients with FPLD2, MAD and HGPS
[3,11,12], including cellular replicative senescence and
prelamin A accumulation [13-15]. Although the patho-
physiological mechanisms leading to LMNA-linked pre-
mature aging are not fully understood, a major hypothesis
is that alterations in maturation and farnesylation of lamin
A induce genomic instability, abnormal epigenetic control
of heterochromatin and DNA damage responses, and
mesenchymal stem cell defects [16-18].
Werner syndrome (WS) is an autosomal recessive
premature aging syndrome due to biallelic inactivating
mutations in WRN, encoding a RecQ DNA helicase/exo-
nuclease involved in DNA replication and repair [19]. Its
prominent features, occurring after adolescence, associate
“bird-like” facies, scleroderma-like skin changes with tight
and atrophic skin, bilateral cataracts, short stature and
premature greying of scalp hair [20]. An initial clinical
presentation as a lipodystrophic syndrome has not been
previously described.
In women with familial partial lipodystrophies, decreased
fertility and obstetrical complications have been reported to
be mainly linked to insulin resistance and metabolic distur-
bances, with an increased prevalence of polycystic ovary
syndrome, gestational diabetes and eclampsia [21,22]. The
mechanisms leading to decreased fertility in Werner syn-
drome have not been deciphered. Only rare cases of preg-
nancies have been reported in women with probable, but
not genetically-confirmed Werner syndrome [23-26].
Here we report the cases of two women investigated
for lipodystrophy and severe insulin resistance, which
revealed Werner syndrome due to homozygous or com-
pound heterozygous, non-sense or frameshift mutations
in the WRN gene. The two patients became pregnant
after initiation of metformin therapy. Both pregnancies
were complicated by cervical incompetence, leading to
a second-trimester abortion in one case and to a pre-
term delivery in the other patient. Cultured fibroblasts
obtained from one patient showed cellular senescence,
nuclear dysmorphies, and lamin staining abnormalities
similar to those found in laminopathies, but did not
overexpress immature prelamin A.Our study points out that primary defects in DNA
replication and/or repair should be considered as pos-
sible causes of lipodystrophic syndromes with extreme
insulin resistance. In addition, we show that cell nuclear
dysmorphies with alterations in lamin staining can be
secondary to cellular senescence of different origin.
Patients and methods
Patients
Two women of 32 and 36 years old were referred to us
for partial lipodystrophic syndrome. Clinical, biological,
molecular, and cellular studies were performed after full
written informed consent, according to the ethic com-
mittee of Hôpital Saint-Antoine, in line with the Helsinki
Declaration.
Phenotype and genotype characterization
Skinfolds thickness was measured using a Harpenden cal-
liper. Routine serum measurements and 75g-oral glucose
tolerance tests (OGTT) were performed after an overnight
12-h fast. Serum adiponectin and leptin levels were deter-
mined by ELISA (Quantikine, R&D Systems, Oxford, UK),
on frozen-stored samples.
Genomic DNA from the two patients was extracted from
peripheral blood leukocytes. The entire coding region and
splice junctions of LMNA, PPARG and/orWRN were amp-
lified and sequenced. DNA from patient 1’s placenta and
from foetal liver and muscular tissues was extracted for dir-
ect sequencing of exon 19 of theWRN gene.
Cellular studies
Cell cultures
Primary fibroblast cultures were established after skin
biopsies in patient 1 and in two control women aged 20
and 33, without known disease, who underwent cos-
metic surgery. Fibroblasts were grown in DMEM medium
(Gibco® Cell Culture, Invitrogen Corporation, San Diego,
CA, USA) containing 1 g/L glucose, 20 mM L-glutamine,
25 mM Hepes, 110 mg/ml sodium pyruvate, 10% foetal
bovine serum (FBS, Gibco), 100 U/ml penicillin and 0.1
mg/ml streptomycin (Invitrogen Corporation) at 37°C in
5% CO2/95% air.
Western blot analysis
Western blot analyses were performed on whole cell ex-
tracts using antibodies directed against lamin-A/C (MAB-
3211, Chemicon International Inc. Temecula, CA, USA),
total prelamin-A (SC-6214, Santa Cruz Biotechnology,
CA, USA), or uncleaved prelamin-A isoforms (i.e.,
containing the CSIM C-terminal aminoacids, farnesylated
or not) (ANT0045, 1188–1, Diatheva, Fano, Italy) [27],
lamin B1 (ab16048, Abcam, Cambridge, UK) and beta-
actin (A5441; Sigma-Aldrich, Saint-Louis, MO, USA).
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Immunofluorescence studies were performed on fibro-
blasts grown on glass coverslips after fixation in methanol
at −20°C, as previously described [15]. DAPI (4’,6’-di-
amidine-2-phenylindole dihydrochloride) was used for nu-
clear staining. Antibodies directed against lamin-A/C
(MAB-3211) and B type-lamins (a generous gift from JC.
Courvalin and B. Buendia, Institut Jacques Monod,
France [11,28]) were revealed by using secondary anti-
bodies coupled to Texas Red or CyTM2 (Jackson
Immuno Research Laboratories, West Grove, PA, USA).
A total of 350 to 550 nuclei was examined and counted
for each subject. Images were acquired and processed
using Adobe Photoshop software after visualisation by
conventional microscopy.
Reactive Oxygen Species (ROS) production
We used the CM-H2DCFDA derivatives (5- (and 6)-
chloromethyl-2’,7’-dichlorodihydrofluorescein diacetate,
acetyl ester, C6827, Molecular Probes) as cell-permeant in-
dicators of ROS [15]. Cells were cultured in 96-well plates,
then washed and incubated with CM-H2DCFDA (9 μM)
or DAPI (0.01 μg/ml) in DMEM medium without FBS for
2 h at 37°C in the dark. Quantification, performed with a
plate fluorescence reader (Spectrafluor Plus, Tecan-France,
Trappes, France) at 520 nm (CM-H2DCFDA) or 465 nm
(DAPI), was normalized to the DNA content.
Senescence-associated beta-galactosidase assay
Physiological lysosomal and senescence-associated beta-
galactosidase activities were assessed by cellular X-gal blue
staining at pH 4 and pH 6, respectively. Cells were fixed
for 10 min at 22°C with 2% formaldehyde/0.2% glutaralde-
hyde, incubated overnight at 37°C in 1 mg/ml 5-bromo-
4-chloro-3-indolyl-ß-D-galactoside (X-gal), 40 mM citric
acid-sodium phosphate (pH 6 or 4), 5 mM potassium
ferricyanide, 5 mM potassium ferrocyanide, 150 mM NaCl
and 2 mM MgCl2, then lysed in H2O and sonicated. The
blue X-gal cellular staining was quantified at 630 nm. The
ratio of pH 6 to pH 4-staining specifically represented
senescence-activated beta-galactosidase activity.
Pathological and histological analyses
Macroscopic analyses of placenta and foetus were
performed two days after abortion. Light microscopy
was performed on 10% formol-fixed paraffin-embedded
5-mm tissue sections, stained with hematoxylin-eosin.
Statistical analyses
All experiments were performed at least three times on
triplicate samples. Quantitative results are expressed as
mean ± SEM. Comparisons between WRN-mutated and
control cells were made with Student’s t-test. P values of
less than 0.05 were considered significant.Results
Case reports
Patient 1
A 32-year-old woman was referred to our Endocrinology
Department for partial lipodystrophy. Her parents, with-
out known consanguinity, originated from close villages of
Madere Island, Portugal. Her medical history was un-
eventful until puberty, when she complained of myalgia
during exercise. Pubertal development was normal with
spontaneous menarche at age 11, followed by primary
oligomenorrhea with menstrual cycles of 30 to 60 days. A
first-trimester spontaneous miscarriage was reported at
age 27. She had been treated a few months ago with
amitryptiline then lamotrigine for painful peculiar
peripheral neuropathy of the limbs (Sorel at al, manu-
script in preparation). Physical examination showed
lipoatrophy of the four limbs, including palms and soles,
but sparing the face, and contrasting with truncal and
abdominal subcutaneous fat accumulation (Figure 1).
Peripheral lipoatrophy and central fat accumulation
appeared progressively since puberty. Loss of muscle
mass from the limbs was striking. Height was 158 cm,
weight 60 kg (body mass index, BMI: 24 kg/m2), waist
and hip perimeters 92 and 96 cm, respectively. Skin
examination revealed livedo reticularis, dry, tight and
atrophied skin, petechiae, purpuric lesions and hyper-
keratosis, predominant in the extremities (Figure 1). No
acanthosis nigricans or hirsutism were observed. Blood
pressure was 120/70 mmHg. Cardiac examination was nor-
mal. Further inquiry revealed that hair graying appeared
since age 25 and surgical extraction of bilateral cataracts at
age 26. Among the five siblings of the patient, a brother
died at 44 years old from myocardial infarction; he was
reported with dysmorphic features, premature cataracts,
insulin-treated diabetes since age 26, and severe athero-
sclerosis leading to foot amputation at age 38. A 42 yr-old
sister died from sarcoma of the quadriceps femoris muscle.
Biological investigations revealed severe insulin resist-
ance with moderate fasting hyperinsulinemia (168 pmol/L,
normal value < 100) reaching extremely high values after
oral glucose tolerance test (OGTT) (maximal value 53800
pmol/L at T60 min, then 29750 pmol/L at T120 min, nor-
mal < 520), without altered glucose tolerance (Table 1 and
Figure 2). Hypertriglyceridemia was associated with low
HDL-cholesterol and slightly elevated alanine transamin-
ase (ALT) and gamma-glutamyl transferase (GGT) levels.
Sex-hormone binding globulin (SHBG) and adiponectin
levels were low. Pituitary-ovarian functions and testoster-
one level were normal, but serum anti-müllerian hormone
(AMH) and inhibin B were not detectable, suggesting de-
creased ovarian reserve (Table 1). Pelvic and transvaginal
sonography showed a normal uterus but enlarged ovaries
(right : 6.2 cm2, left : 6.9 cm2, normal volume < 5.5 cm2)
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Figure 1 (See legend on next page.)
Donadille et al. Orphanet Journal of Rare Diseases 2013, 8:106 Page 4 of 13
http://www.ojrd.com/content/8/1/106
(See figure on previous page.)
Figure 1 Clinical features of patients. Photographs of patient 1, aged 32 (1, A, B, C, D, E) and patient 2, aged 36 (2, F, G, H, I, J), showing
partial lipodystrophy with subcutaneous fat accumulation of the trunk and abdomen with lipoatrophy of the limbs including palms and soles
(1, A, B, D, C, E), livedo reticularis of the limbs (B, D, G), sclerodactylia (C, E, I, J), dry, tight and atrophic skin with hyperkeratosis of extremities
(B, C, D, E, H, I, J).
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cardial scintigraphy were normal, whereas doppler
ultrasonography evidenced a mildly increased carotid
intima-media thickness (0.9 mm, normal < 0.6 mm).
Other investigations revealed mild sensorineural hearing
loss. A whole-body MRI did not reveal any neoplasm.
Peripheral lipoatrophy was quantified by skinfold
thickness measurements (Figure 3A). Whole-body dual-
energy X-ray absorptiometry (DEXA) revealed increasedTable 1 Biological features of patients
Patient 1
Fasting glycemia (mmol/L) 5.1
Fasting insulinemia (pmol/L) 168
2 h post-OGTT glycemia (mmol/L) 6.5
2 h post-OGTT insulinemia (pmol/L) 29750
HbA1c (%) 6.8




Alanine transaminase (ALT) (IU/L) 47
Aspartate transaminase (AST) (IU/L) 24
Gamma-glutamyl transferase (GGT) (IU/L) 60
Leptin (μg/L) 33
Adiponectin (mg/L) 0.8
Sex-hormone binding globulin (nmol/L) 14
Insulin-like growth factor 1 (IGF-1) (μg/L) 166
Thyroid stimulating hormone (TSH) (mU/L) 4.8
Free T4 (μg/L) 9.4
Follicle stimulating hormone (FSH) (IU/L) 7.5
Luteinizing hormone (LH) (IU/L) 3.2
Estradiol (pmol/L) 215
Total testosterone (nmol/L) 0.96
Androstenedione (nmol/L) 4.9
Dehydroepiandrosterone sulfate (mmol/L) 2.4
Prolactin (μg/L) 6.6
Anti-Müllerian hormone (pmol/L) <0.3
Inhibin B (ng/L) < 10
OGTT oral glucose tolerance test.
Hormone measurements were performed in early follicular phase.
Anti-Müllerian hormone and inhibin B levels were measured at age 33 for patient 1body fat, predominantly distributed in the trunk area, in
accordance with the clinical findings (Figure 3B). Bone
mineralization was normal. MRI imaging showed
that peripheral lipoatrophy affected the four limbs
(Figure 4A). In the thighs, subcutaneous fat was asym-
metrically distributed, with normal medial but reduced
postero-lateral adipose tissue (Figure 4A). MRI also
showed a severe loss of gluteal fat and an increase in





























Figure 2 Baseline oral glucose tolerance tests of patients, before metformin therapy. G, glycemia (circles, blue), and Ins, insulinemia
(squares, red) from patients 1 (filled symbols) and 2 (empty symbols) are depicted.
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steatosis.
Sequencing of LMNA and PPARG did not reveal any
alteration. WRN sequencing revealed homozygosity for a
c.2242C>T transition in exon 19, predicting the synthe-
sis of a p.Q748X WRN protein, truncated in its helicase
domain, which was absent in 100 unrelated control
subjects.
Appropriate diet and metformin therapy decreased insu-
lin resistance, although insulinemia remained elevated
(respectively 130 and 1600 pmol/l at OGTT T0 and T120
min after three months, with normal glycemia). Statin and
fibrate treatments were poorly tolerated, due to muscular
pain.
One year later, after six years of infertility, the patient
became spontaneously pregnant. She developed gesta-
tional diabetes, treated with diet and insulin. At 10 weeks
of pregnancy, a short cervix (18 mm) was noted and a cer-
vical cerclage was performed. Obstetrical ultrasound scan
was normal at 16 weeks, but premature rupture of mem-
branes, followed by spontaneous abortion occurred at 20
weeks of gestation. Pathological examination of the pla-
centa showed signs of chorioamnionitis and funiculitis,
which did not allow precise evaluation of possible previousvascular alterations (Figure 5A). The female foetus
weighted 294 g (normal for gestational age), and showed a
craniofacial dysmorphy associating retrognatism, receding
forehead and flat nasal bridge, that could be linked to
prolonged oligohydramnios due to premature rupture of
membranes. X-ray analysis of the whole skeleton was nor-
mal. Foetal histopathological examination only revealed
hyperplasia of pancreatic Langerhans islet cells (Figure 5B).
Heterozygosity for the p.Q748X WRN mutation was ob-
served in placental and foetal DNA.
Patient 2
A 36-year-old woman was referred for partial lipo-
dystrophy. She was born from non-consanguineous healthy
parents of Sicilian and French origin. Her two siblings, a
34-yr old sister and a 38-yr old brother, were also reported
to be healthy. Her medical history was uneventful until
age 30, when she underwent surgical removal of a
chondrosarcoma of the right distal femur (with total knee
prosthetic replacement). At this time a 2 g/l fasting gly-
cemia was observed, in the absence of antibodies directed
against glutamic acid decarboxylase 65 and tyrosine phos-
phatase (anti-GAD and anti-IA2); BMI was 20.3 kg/m2.
Hypertriglyceridemia reached 4 g/l, and liver steatosis was
B
Percentage of fat (DEXA)
Total Trunk Upper limbs
Lower 
limbs
Patient 1 40.0 46.7 39.3 27.5
Patient 2 24.7 30.9 24.3 14









Figure 3 Body fat distribution of patients: Skinfold thickness
and whole-body dual-energy X-ray absorptiometry (DEXA). (A)
Skinfold thickness measured in patient 1 (dark grey squares) and
patient 2 (light grey squares) as compared to that reported in typical
FPLD2 women with LMNA p.R482 heterozygous substitutions (white
rectangles) and control women (black rectangles) [29,30]. Median
and range values are indicated. (B) Results of DEXA in patients 1 and
2, showing that body fat was predominantly distributed in the trunk
area. Normal values (mean ± SD) are from [31].
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ALT and GGT in the absence of any other cause. Meta-
bolic alterations were controlled using diet, fibrates and α-
glucosidase inhibitors. Regarding gynecological history,
puberty was normal, with spontaneous menarche at age
11, and regular menstrual cycles of 28 days. A first-
trimester spontaneous miscarriage was reported at age 34.
Since then, she did not conceive and consulted for 2 year
infertility. At examination, she presented a partial
lipodystrophy phenotype, with lipoatrophy and loss of
muscle mass of the four limbs, palms and soles, which
progressively appeared since age 20. Lipoatrophy spared
the face, which contrasted with truncal and abdominal
subcutaneous fat accumulation (Figure 1 and Figure 3A).
Height was 144 cm, weight 39 kg (BMI: 18.8 kg/m2), waist
and hip perimeters 76 cm. A high-pitched voice was
noted. Skin examination revealed livedo reticularis on the
limbs, with dry, tight, atrophied skin and hyperkeratosis,
predominant in the extremities (Figure 1). No acanthosis
nigricans or hirsutism were observed. Blood pressure was
110/60 mmHg. Cardiac examination was normal but dop-
pler monitoring revealed diffuse atherosclerosis. Further
inquiry revealed that hair graying appeared since age 12,
and bilateral cataracts were diagnosed at age 34.OGTT revealed severe hyperinsulinemia (fasting and
T120 min values, 371 and 8884 pmol/L, respectively) with
diabetes (glycemia was normal at fast but reached 12.2
mmol/L at T120 min OGTT) (Table 1 and Figure 2).
Hypertriglyceridemia was associated with slightly low
HDL-cholesterol and elevated ALT and GGT. Leptin was
normal for BMI. SHBG and adiponectin levels were low.
FSH and testosterone levels were normal, but AMH and
inhibin B very low (Table 1).
Peripheral lipoatrophy was assessed by skinfold thickness
measurements (Figure 3A) and by MRI imaging. As for pa-
tient 1, MRI showed asymmetrical distribution of subcuta-
neous fat in the thighs and increased intra-abdominal fat
stores (Figure 4). DEXA confirmed that fat was predomin-
ant in the trunk and reduced in the lower limbs (Figure 3B).
Bone mineral density was low (−2 and −2.8 SD at the verte-
bral and the femoral levels, respectively).
WRN sequencing revealed previously undescribed com-
pound heterozygous mutations, with a c.3769C>T transi-
tion in exon 32 predicting a p.Q1257X truncation, and a
c.3986delT frameshift deletion in exon 34 predicting the
synthesis of a 1333 amino acid p.M1329fs WRN truncated
protein, both mutated proteins lacking their nuclear
localization signal. These mutations were absent in 100
unrelated control subjects.
Metformin was added to the treatment of the patient,
and she became pregnant two months later. Insulin ther-
apy was needed from the second month of pregnancy. A
prophylactic cervical cerclage was performed at 15 weeks
of gestation, but premature rupture of membranes with
preterm labor occurred at 21 weeks. Treatment allowed
the maintenance of pregnancy until 31 weeks, when a cae-
sarean section was performed for chorioamnionitis. The
patient gave birth to a healthy female child of 2310 g (nor-
mal for gestational age) with normal clinical examination
except for the presence of a receding forehead without
radiological signs of craniodysostosis. X-ray analysis of the
whole skeleton, and cardiac and abdominal echography
were normal. Placental histological examination confirmed
the diagnosis of chorioamnionitis but did not reveal other
specific alterations.
Cell studies
Primary fibroblast cultures from patient 1 were studied
in comparison to control cells and/or to cells from a pa-
tient with FPLD2 due to the heterozygous p.R482W
LMNA mutation [15], at the same passage.
Fibroblasts from patient 1 showed nuclear shape
abnormalities without altered expression and localization of
type A lamins
Nuclear shape abnormalities, with lobulations and blebs,
were more prevalent in patient 1’s than in controls’ cells,
studied at the same early passage (mean ± SEM : 18.4 ± 4.1
AB Patient 1 Control woman
Figure 4 Body fat distribution of patients: magnetic resonance imagery (MRI). (A). T1-weighted MRI axial scans through the arm, forearm,
thigh, calf and abdomen of patients 1 and 2, compared with a control woman of similar age (35 yr-old) and BMI (23 kg/m2). Partial lipoatrophy
affecting the four limbs, contrasting with accumulation of intra-abdominal fat, was evidenced in both patients. Increased subcutaneous
abdominal fat was also striking in patient 1. Bone marrow fat was well preserved. (B). T1-weighted MRI pelvic axial scan in patient 1 and in a
control woman (BMI 21 kg/m2), showing lipoatrophy of gluteal fat depots with accumulation of anterior abdominal subcutaneous fat in patient 1.
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blebs showed altered lamin A/C staining and were
frequently devoid of lamin B, with a weak DNA staining
suggesting chromatin decondensation, as shown by im-
munocytochemistry (Figure 6A). Protein expression of type
A-lamins was not different, but lamin B1 levels were in-
creased in fibroblasts from patient 1, as compared to
control or LMNA p.R482W-mutated cells. Prelamin A,
which is known to be accumulated in p.R482W LMNA-mutated cells [15], was not detectable in control and pa-
tient 1’s cells (Figure 6B).
Fibroblasts from patient 1 showed increased oxidative
stress and premature senescence
Oxidative stress, assessed by cellular ROS production, was
increased in fibroblasts from patient 1 as compared to
controls, at the same passage (Figure 6C). The WRN-mu-
tated fibroblasts also prematurely acquired a senescence-
A B
Figure 5 Pathological features of placenta and foetus from
patient 1 (hematoxylin-eosin staining). (A) Placenta villosities
examination. (B) Hyperplasia of Langerhans islet cells from the
foetus’s pancreas.
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and have a significantly increased senescence-associated
ß-galactosidase activity, as compared to control cells of
the same passage (Figure 6D).
Discussion
In the present study, we add further evidence for a
pathophysiological link between cellular senescence and
lipodystrophy, by showing for the first time that partial
lipodystrophy syndrome with extreme insulin resistance
can be the initial referring presentation of the adult pro-
geria Werner syndrome, due to a primary defect in the
WRN enzyme, involved in DNA replication and repair.
Lipodystrophic syndromes are heterogeneous diseases of
genetic or acquired origin, characterized by generalized or
partial lipoatrophy associated with insulin resistance. Re-
cent advances in molecular genetics have shown that pri-
mary defects in fat differentiation and/or adipose lipid
droplet formation or maintenance are the main causes of
genetic lipodystrophies (for review, see [32-34]). However,
the hypothesis that lipodystrophy could also be secondary
to primary mesenchymal cellular senescence was raised by
the studies of laminopathies, which collectively name a
group of diseases due to alterations in the ubiquitous nu-
clear intermediate filaments A type-lamins, encoded by
the LMNA gene. Indeed, mutations in LMNA can lead to
Dunnigan-type familial partial lipodystrophy (FPLD2)
[5,6], but also to accelerated ageing syndromes [1-4], and
to mixed overlapping phenotypes with both lipoatrophy,
metabolic complications and progeroid signs [7-10]. In
addition, cellular studies have shown that, although lamin
A alterations could impair adipogenesis through
mislocalisation of the key adipogenic transcription factor
SREBP1c [14,35-37], premature cellular senescence prob-
ably also participates to the pathophysiology of LMNA-
linked lipodystrophy [15].
Werner syndrome, also called adult progeria (OMIM
277700), is one of several progeroid syndrome due to de-
fective DNA helicases (for review, see [20]). This segmen-
tal aging syndrome, affecting several organ systems, is dueto recessive null mutations in the WRN protein, which ex-
hibits exonuclease, ATPase and helicase activities. Cellular
senescence associated with Werner syndrome has been
linked to DNA replication and repair defects [19]. The
clinical diagnostic criteria have been defined by the
International Registry of Werner Syndrome (http://www.
wernersyndrome.org/registry/diagnostic.html) [20], and
have been recently revised on the basis of the results of a
Japanese nationwide epidemiological survey [38].
Both patients described here were referred for partial
lipodystrophy, which is not listed as a classical sign of
the disease. Several lipodystrophic features were differ-
ent to those usually observed in other types of partial
lipoatrophic syndromes, as FPLD2 or 3 due to LMNA or
PPARG mutations, respectively. Indeed, in both patients,
peripheral lipoatrophy was associated with loss of limb
muscles, which contrasted with the muscle hypertrophy
associated with FPLD2 and 3. In addition, marked cen-
tral adiposity was striking, and imagery revealed an
asymmetrical distribution of subcutaneous fat in the
thighs. Both patients also exhibited several cardinal signs
of Werner disease, i.e. bilateral cataracts, tight and atro-
phied skin with hyperkeratosis, and premature greying of
scalp hair. In addition, patient 2 had short stature, and
two siblings of patient 1 were probably affected, although
molecular analysis was not possible. Further signs, listed
as reminiscent of Werner disease, were also present: ath-
erosclerosis and altered fertility in both cases, and high-
pitched voice, diabetes, osteoporosis and mesenchymal
neoplasm in patient 2. In both patients, we identified trun-
cating null mutations affecting both alleles of WRN gene
with loss of the nuclear localization signal. The homozy-
gous p.Q748X WRN mutation of patient 1 was previously
found in a Caucasian man diagnosed with Werner syn-
drome, but his clinical features were not reported [20],
whereas patient 2 was affected by new WRN mutations.
No evident genotype-phenotype correlations have been
reported in Werner syndrome [20,39], although proximal
truncation of WRN protein could lead to severe pheno-
types [40]. Further studies are needed to eventually link
the lipodystrophic clinical presentation to specific WRN
mutations. However, our report shows that Werner syn-
drome is an important differential diagnosis in patients
initially presenting with partial lipodystrophy as a promin-
ent feature, leading to a specific follow-up, in particular re-
garding cancer risk, gynecology, and genetic counseling.
These two women presented with severe insulin re-
sistance, with insulinemia being dramatically increased
during OGTT without hypoglycemia. Low SHBG and
adiponectin levels suggest a post-receptor insulin sig-
nalling defect, as observed in other lipodystrophic syn-
dromes, where ectopic fat deposition, particularly in
muscle and liver, is thought to play a major role in insu-
lin resistance [41]. In accordance, our patients had also
Figure 6 WRN-mutated fibroblasts showed nuclear shape abnormalities, oxidative stress and premature senescence, without altered
expression and localization of type A lamins. Cultured skin fibroblasts from patient 1 were compared to control cells. (A) Nuclear staining of
fibroblasts was performed with diamidino-2phenylindole hydrochloride (DAPI) (DNA, blue), and with antibodies directed against lamin A/C (red),
and lamin B (green). Representative cells, studied at passages 4 to 8, are shown. Lamin A/C staining was heterogeneous and lamin B staining
reduced or absent in nuclear blebs or poles of dysmorphic WRN-mutated cells, but not in control cells. Scale bars represent 10 μm. Quantification
of cells with dysmorphic nuclei was performed after examination of 200 to 250 cells for each subject. Results are expressed as mean ± SEM. ***,
p < 0.001. (B) Fibroblast lysates were submitted to Western blot, using antibodies which specifically detect lamin A/C (MAB3211), lamin B1
(ab16048), prelamin A (SC-6214), and uncleaved prelamin A (having retained its CSIM C-terminal tail) (ANT0045). Beta-actin was used as a loading
control. Representative results from control, WRN-mutated, and p.R482W LMNA-mutated cells, used as positive controls [15], are shown as
indicated. (C) ROS production was assessed by oxidation of CM-H2DCFDA derivatives, normalized to the DNA content, and senescence-associated
ß-galactosidase cell activity by the ratio of X-gal staining at pH6 and pH4, in WRN-mutated and control fibroblasts studied at the same passage
(2 to 5). Results from four experiments performed in quadriplate are shown, as mean ± SEM. *, p < 0.05, ***, p < 0.001. (D) Representative
micrographs of cells stained with X-gal at pH 6 are shown. Control cells were studied at passage 1 to 4, and WRN-mutated cells at passage 1.
Note the senescence-associated blue staining, flattened and enlarged morphology of WRN-mutated cells. Scale bars represent 40 μm.
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eral skinfolds confirmed a severe subcutaneous
lipoatrophy of the limbs, whereas percentage of fat mea-
sured by DEXA in limbs was increased or only slightly
decreased, suggesting that the limb muscles could be in-
filtrated with lipids. Insulin resistance has been previ-
ously reported in patients with Werner syndrome, with
hypoadiponectinemia and increased intra-abdominal
visceral fat in some patients [42,43], but insulin values
did not reach such dramatically elevated levels [43,44].
Therefore, our report suggests that the presence of amarked lipodystrophy can contribute to the severity of
insulin resistance in Werner syndrome.
Our report also points out the specific gynecological
and obstetrical complications of Werner syndrome. Hypo-
gonadism is a classic sign of Werner syndrome, but its
precise origin has not been investigated [20,38]. To our
knowledge, only three pregnant women with clinically-
suspected, but not genetically-confirmed Werner syn-
drome, have been previously reported [23-26]. None of
them carried their pregnancies to full-term, with spontan-
eous abortions at 10, 16 and 23 weeks [23], or preterm
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sufficiency in three cases [23,24] or to caesarean section
for maternal life-threatening ischemic heart disease in one
case [25,26]. Preeclampsia occurred during two pregnan-
cies, in the absence of diabetes [23], and placental vascular
alterations were observed in one case [24]. Our two pa-
tients had experienced early spontaneous abortions and
had reduced fertility. They both became pregnant during
the follow-up, but severe cervical incompetence, which
thus appears to be a frequent obstetrical complication in
this disease, led to a preterm birth in one case, and to a
second term-abortion in the other. No specific abnormal-
ity was evidenced in the foetus and the preterm newborn.
Pancreatic islet hyperplasia observed at foetal autopsy was
linked to gestational diabetes. The placenta showed signs
of chorioamnionitis and funiculitis, which were secondary
to premature rupture of membranes.
In these women, reduced fertility was probably related
to a premature decrease in the pool of primordial ovarian
follicles (diminished ovarian reserve). Indeed, although
their menstrual cycles were not modified, and their FSH
levels were still within normal range, indicating that they
did not had premature ovarian failure, their AMH and in-
hibin B serum levels were very low [45]. Biological ovarian
hyperandrogenism, observed in patient 2, and polycystic
ovaries in patient 1, favored by extreme insulin resistance,
could also have contributed to decreased fertility. In ac-
cordance, both pregnancies were obtained after reducing
hyperinsulinemia with metformin treatment. Therefore,
both insulin resistance and premature ovarian ageing
could lead to decreased fertility in Werner syndrome.
Lipodystrophic and progeroid laminopathies are charac-
terized by cellular senescence and nuclear dysmorphies,
with nuclear blebs showing abnormal nuclear staining of
A and B-type lamins [3,11,12,15,46]. Several studies have
suggested that accumulation of farnesylated forms of
prelamin A could underlie these abnormalities (for review,
see [47]). Our present results show that fibroblasts with
WRN null mutations present nuclear deformations similar
to those observed in laminopathies, as described in one
previous study [48]. We also showed that oxidative stress
and cellular senescence were enhanced in WRN-mutated
cells. However, prelamin A was not accumulated in
WRN-mutated cells, suggesting that primary DNA re-
pair defects and LMNA alterations act by different mech-
anisms to induce premature ageing. In addition, although
lamin B staining was decreased in nuclear blebs, the over-
all lamin B1 protein expression was increased in WRN-
mutated cells, which was not previously described in
laminopathies. The role of B type-lamins in cellular senes-
cence is complex [49]. Indeed, replicative or oncogene-
induced senescence has been linked to underexpression of
lamin B1 [50], but oxidative stress-induced senescence to
overexpression of lamin B1 [51]. An interesting hypothesisis that cellular stresses which alter the normal ratio of
lamin B1 to functional lamin A, lead to deleterious
changes in nuclear lamina, then senescence [49]. In ac-
cordance, and in line with our results, cells from pa-
tients with ataxia-telangiectasia, another genetic disease
due to DNA damage signalling defects, display a state of
endogenous oxidative stress which induces lamin B1
overexpression, nuclear shape alterations and senes-
cence through MAP kinase activation [51]. It is possible
that MAP kinase activation, which was previously ob-
served in Werner syndrome [52], could also contribute
to lamin B1-linked cellular senescence. Whether WRN-
linked lipodystrophy could be secondary to primary
mesenchymal cellular senescence, as it was suggested in
laminopathies, needs to be further investigated.Conclusion
This report points out that partial lipodystrophic syn-
drome with severe insulin resistance can reveal Werner
syndrome due to WRN mutations. Therefore, the search
for clinical and biological arguments in favor of this diag-
nosis is mandatory in patients with partial lipodystrophies.
In addition to some clinical features that distinguish
lipodystrophic syndromes due to WRN as compared to
LMNA mutations (as early cataracts and mesenchymal
neoplasms), peculiar gynecological and obstetrical risk fac-
tors, i.e. diminished ovarian reserve and cervical incompe-
tence, also characterize women with Werner syndrome.
From a cellular point of view, this study shows that WRN
mutations induce alterations in type B lamins expression
and localization, with nuclear dysmorphies, that could par-
ticipate to cellular senescence.
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